Importantly, the proposed benefits of PPAR-α activation appear to be mediated by modulation of immune responses and cellular metabolism rather than by lowering circulating cholesterol levels, underscoring the relevance of lipid signaling pathways as potential therapeutic targets in MS [98]. The gene discussed is PPARA; the disease is myeloid sarcoma.